摘要
目的:探讨手术及放、化疗后DC-CIK细胞治疗中晚期恶性肿瘤的临床疗效。方法:回顾性研究531例中晚期恶性肿瘤于手术及放、化疗后静脉输注DC-CIK细胞治疗的疗效及不良反应。结果:经DC-CIK细胞治疗后,OR 47.8%,CBR93.3%,Karnofsky评分增加≥20分者89.8%,T淋巴细胞rDNA转录活性分析(Ag-NORs)IS均值由5.16%增至5.68%,Ⅲ-Ⅳ期3年生存率61.2%,且对外周血象及心、肝、肾功能均无不良影响。结论:DC-CIK细胞安全、有效,能明显增强免疫功能,改善生存质量,提高3年生存率。
Objective：To assess the therapeutic effects of DC-CIK cells immun-otherapy on middle and advanced stage of carcinoma.Methods：The therapeutic effects and side effects of DC-CIK cells immunotherapy on middle and advanced stage carcinoma after operation,chemotherapy and radiotherapy was reviewed.Results：After the treatment,the Ag-NORs rised from 5.16% to 5.68%,89.8% of the patients＇ KPS rised over 20 score,objective response rate（OR） was 47.8%,clinicalbenefit rate（CBR） was 93.3%.The 3-year survival rate was 61.2%.The DC-CIK cells had no adverse influence on the heart function,liver function,renal functionand blood routine.Conclusion：DC-CIK cells are safe and valid on middle and advanced stage carcinoma.They can enhance immune function,ameliorate lifequality and increase 3-year survival rate.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2011年第4期360-362,共3页
Chinese Journal of Immunology
基金
吉林省科技发展计划重点项目(No.20090466)
